Feed
Read More
Amgen (AMGN): a hidden player in the GLP-1 sector with great potential
The GLP-1 weight loss drugs market is one of the fastest growing segments of the healthcare industry and could reach a value of $200 billion by 2031. So far, Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the market, but their shares are trading at extremely high earnings multiples. Amgen $AMGN may become a...
Read more
Read More
Amgen and its MariTide programme: Is the stock drop worth the buying opportunity?
Amgen $AMGN recently disclosed the results of its obesity treatment candidate MariTide, which has completed Phase II clinical trials. Although the stock responded with a drop of more than 12%, it closed the day with only a 4.7% decline. The market viewed the results as less promising compared to...
Read more
Zobrazit další komentáře
Overall, the industry has a lot of potential right now. I'm probably most interested in $NVO so far and the stock is pretty down right now, so I'm thinking about buying.
I'd like to buy $LLY stock, but the valuation is too high right now.